"Mark brings to PhotoSonix extensive operating and commercialization expertise with both a large company and small company perspective," said Adam Dakin, President & CEO of PhotoSonix. "We are honored to welcome him to our Board."
"PhotoSonix has developed a novel approach to the treatment of acne, a large market without many effective solutions. CLENS™ represents a new type of technology that could bring superior relief to millions of acne sufferers," said Steele. "The company's mission and science driven approach aligns with my passion for developing new dermatological solutions that deliver superior efficacy."
About PhotoSonix Medical
PhotoSonix's patented CLENS™ (Combined Light Energy and Non-focused ultraSound) combines ultrasound with blue light. The company's innovative platform targets biofilm-based infections which include acne. PhotoSonix is backed by Princeton Biopharma Capital Partners, Ben Franklin Technology Partners, and a sophisticated group of angel investors.
Approximately 20 million patients in the US have acne severe enough to cause scarring. Expenditures on acne treatment in the US exceed $3 billion.
Note: The CLENS™ System is an investigational device and not available for commercial use in the United States.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/photosonix-medical-appoints-former-neostrata-ceo-mark-d-steele-to-board-of-directors-300409116.html
SOURCE PhotoSonix Medical, Inc.